Pluripotent stem cell-derived hepatocytes: Potential and challenges in pharmacology

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 147-159

  Szkolnicka, Dagmara ^a   Zhou, Wenli ^a,b   Lucendo Villarin, Balta ^a   Hay, David C ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

cytochrome p450 metabolism; drug induced liver injury; genetics; human embryonic stem cell; induced pluripotent stem cell

Indexed keywords

CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL REGENERATION; CELL THERAPY; EXTRACELLULAR MATRIX; HUMAN; LIVER DISEASE; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PLURIPOTENT STEM CELL DERIVED HEPATOCYTE; PRIORITY JOURNAL; REVIEW;

ANIMALS; HEPATOCYTES; HUMANS; LIVER; PLURIPOTENT STEM CELLS;

EID: 84872232500     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011112-140306     Document Type: Review

References (82)

1. Saxema R, Zucker S, Crawford J. 2003. Anatomy and physiology of the liver. In Hepatology: A Textbook of Liver Disease, ed. DZ Zakim, TD Boyer, pp. 3-30. Philadelphia: Saunders
2. Musana K, Yale S, Abdulkarim A. 2004. Test of liver injury. Clin. Med. Res. 2(2):129-31
3. Adams L, Angulo P. 2006. Treatment of non-alcoholic liver disease. Postgrad. Med. J. 82:315-22
4. Duffield S,Forbes SJ, Constandinou C, Clay S, Partolina M, et al. 2005. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Investig. 115(1):56-65
5. Battaler R, Brenner D. 2005. Liver fibrosis. J. Clin. Investig. 115(2):209-18
6. Iredale JP. 2007. Models of liver fibrosis exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Investig. 117(3):539-48
7. Gines P, Cardenas A, Arroyo V, Rodes J. 2004. Management of cirrhosis and ascites. N. Engl. J. Med. 350:1646-54
8. Schrader J, Gordon-Walker T, Aucott R, vanDeemterM,Quaas A, et al. 2011. Matrix stiffnessmodulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology 53(4):1192-205
9. Vara D, Salazar M, Olea-Herrero N, Guzm̄an M, Velasco G, Diaz-Laviada I. 2011. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 8(7):1099-111
10. Xie HG, Kim RB, Wood AJJ, Stein CM. 2001. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41:815-50
11. Wilkinson G. 2005. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352:2211-21
12. Jancova P, Anzenbacher P, Azenbacherova E. 2010. Phase II drug metabolizing enzymes. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 154(2):103-16
13. Chen Y, Tseng H, Kuo W, Yang S, Chen DR, Tsai HT. 2010. Glutathione S-transferase P1 (GSTP1) gene polymorphism increases age-related susceptibility to hepatocellular carcinoma. BMC Med. Genet. 11:46
14. Kaplovitz N. 2004. Drug-induced liver injury. Clin. Infect. Dis. 38:44-48
15. Inoue H, Yamanaka S. 2011. The use of induced pluripotent stem cells in drug development. Clin. Pharmacol. Ther. 89(5):655-61
16. Wang Z, Gerstein M, Snyder M. 2009. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10:57-63
17. Heinrich R, Schuster S. 1996. The Regulation of Cellular Systems. New York: Chapman & Hall
18. Papin J, Stelling J, Price N, Klamt S, Schuster S, Palsson B. 2004. Comparison of network-based pathway analysis methods. Trends Biotechnol. 22:400-5
19. Schuster S, von Kamp A, von Pachko M. 2007. Understanding the roadmap of metabolism by pathway analysis. Methods Mol. Biol. 358:199-226
20. Lee J, Gianchandani E, Papin J. 2006. Flux balance analysis in the era of metabolomics. Brief Bioinforma. 7:140-50
21. Ruppin E, Pappin J, de Figueredo L, Schuster S. 2010. Metabolic reconstruction, constraint-based analysis and game theory to probe genome-scale metabolic networks. Curr. Opin. Biotechnol. 21:1-9
22. Hankowski K, Hamazaki T, Umezewa A, Terada N. 2011. Induced pluripotent stem cells as a nextgeneration biomedical interface. Lab. Investig. 91:927-77
23. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, et al. 2002. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137:947-54
24. Chalasani N, Bj ̈ ornsson E. 2010. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 138(7):2246-59
25. Kaplovitz N. 2002. Biochemical and cellular mechanisms of toxic liver injury. Semin. Liver Dis. 22:137-44
26. Odin J, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A. 2001. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J. Clin. Investig. 108(2):223-32
27. Allain JE, Dagher I,Mahieu-Caputo D, Loux N, Andreoletti M, et al. 2002. Immortalization of a primate bipotent epithelial liver stem cell. Proc. Natl. Acad. Sci. USA 99:3639-44
28. Cai J, Ito M, Westerman KA, Kobayashi N, Leboulch P, Fox IJ. 2000. Construction of a non-tumorigenic rat hepatocyte cell line for transplantation: reversal of hepatocyte immortalization by site-specific excision of the SV40 T antigen. J. Hepatol. 33:701-8
29. Delgado JP, Parouchev A, Allain JE, PennarunG,Gauthier LR, et al. 2005. Long-term controlled immortalization of a primate hepatic progenitor cell line after Simian virus 40 T-antigen gene transfer. Oncogene 24:541-51
30. Wege H, Chui MS, Le HT, Strom SC, Zern MA. 2003. In vitro expansion of human hepatocytes is restricted by telomere-dependent replicative aging. Cell Transplant. 12:897-906
31. Guillouzo A, Corlu A, Aninant C, Glaise D,Morel F, Guguen-Guillouzo C. 2007. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168(1):66-73
32. Mills JB, Rose KA, Sadagopan N, Sahi J, de Morais SM. 2004. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J. Pharmacol. Exp. Ther. 309(1):303-9
33. Davila J, Cezar G, Thiede M, Strom S, Miki T, Trosko J. 2004. Use and application of stem cells in toxicology. Toxicol. Sci. 74:214-23
34. Greenhough S, Hay DC. 2012. Stem cell-based toxicity screening: recent advances in hepatocyte generation. Pharm. Med. 26(2):85-89
35. Dalgetty D, Medine C, Iredale J, Hay DC. 2009. Progress and future challenges in stem cell-derived future technologies. Am. J. Physiol. Gastrointest. Liver Physiol. 297:G241-48
36. Medine C, Greenhough S, Hay DC. 2010. Role of stem-cell-derived hepatic endoderm in human drug discovery. Biochem. Soc. Trans. 38(4):1033-36
37. Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. 2000. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat. Biotechnol. 18:399-404
38. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, et al. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282:1145-47
39. Asahina K, Fujimori H, Shimizu-Saito K, Kumashiro Y, Okamura K, et al. 2004. Expression of the liverspecific gene Cyp7a1 reveals hepatic differentiation in embryoid bodies derived from mouse embryonic stem cells. Genes Cells 9:1297-308
40. Lavon N, Yanuka O, Benvenisty N. 2004. Differentiation and isolation of hepatic-like cells from human embryonic stem cells. Differentiation 72(5):230-38
41. Duan Y, Catan A, Meng Y. 2007. Differentiation and enrichment of hepatocyte-like cells from human embryonic stem cells in vitro and in vivo. Stem Cells 25:3058-68
42. Basma H, Soto-Guttierez A, Yannam GR, Liu L, Ito R, et al. 2009. Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology 136(3):990-99
43. Agarwal S, Holton KL, Lanza R. 2008. Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells 26:1117-27
44. Cai J, Zhao Y, Liu Y, Ye F, Song Z, et al. 2007. Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology 45:1229-39
45. Hay DC, Zhao D, Ross A, Mandalam R, Lebkowski J, Cui W. 2007. Direct differentiation of human embryonic stem cells to hepatocyte-like cells exhibiting functional activities. Cloning Stem Cells 9:51-62
46. Hay DC, Fletcher J, Payne C, Terrace JD, Gallagher RC, et al. 2008. Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signalling. Proc. Natl. Acad. Sci. USA 105:12301-6
47. Medine C, Lucendo-Villarin B, Zhou W, West CC, HayDC. 2011. Robust generation of hepatocyte-like cells from human embryonic stem cell populations. J. Vis. Exp. 56:e2969
48. Medine C, Hannoun Z, Greenhough S, Payne C, Fletcher J,Hay DC. 2012. Deriving metabolically active hepatic endoderm from pluripotent stem cells. In Human Embryonic and Induced Pluripotent Stem Cells: Lineage-Specific Differentiation Protocols, ed. K Ye, S Jin, pp. 369-86. Secaucus, NJ: Springer
49. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 124(6):663-76
50. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:1-12
51. Asgari S, Pournasr B, Salekdeh G H, Ghodsizadeh A, et al. 2010. Induced pluripotent stem cells: a new era of hepatology. J. Hepatol. 58:738-51
52. Rashid S, Corbineau S,HannanN,Marciniak S, Miranda E. 2010. Modelling inheritedmetabolic disorders of the liver using human induced pluripotent stem cells. J. Clin. Investig. 120(9):3127-36
53. Guguen-Guillouzo C, Cĺement B, Baffet G, Beaumont C, Morel-Chany E, et al. 1983. Maintenance and reversibility of active albumin secretion by adult rat hepatocytes co-cultured with another liver epithelial cell type. Exp. Cell Res. 143(1):47-54
54. BernhardtA,Kuester D, Roessner A, Reinheckel T, Krueger S. 2010. CathepsinX-deficient gastric epithelial cells in co-culture with macrophages: characterization of cytokine response and migration capability after Helicobacter pylori infection. J. Biol. Chem. 285(44):33691-700
55. Miki T, Ring A, Gerlach J. 2011 Hepatic differentiation of human embryonic stem cells is promoted by three-dimensional dynamic perfusion culture conditions. Tissue Eng. Part C Methods 17:557-68
56. Miki T. 2011. Hepatic differentiation of human embryonic and induced pluripotent stem cells for regenerative medicine. In Embryonic Stem Cells: Differentiation and Pluripotent Alternatives, ed. MS Kallos, pp. 303-20. Rijeka, Croatia: InTech
57. Hay DC, Perngallo S, Diaz-Mochon J, Medine C, Greenhough S, et al. 2011. Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism. Stem Cell Res. 6:92-102
58. Zhou W, Hannoun Z, Jaffray E, Medine CN, Black JR, et al. 2012. SUMOylation of HNF4αregulates protein stability and hepatocyte function. J. Cell Sci. 125:3630-35
59. Hannoun Z, Fletcher J, Greenhough S, Medine C, Samuel K, et al. 2010. The comparison between conditioned media and serum-free media in human embryonic stem cell culture and differentiation. Cell Reprogram. 12(2):133-40
60. Huang P, He Z, Ji S, Sun H, Wang X. 2011. Induction of functional hepatocyte-like cells from mouse fibroblast by defined factors. Nature 475:386-89
61. Sekiya S, Suzuki A. 2011. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 475:390-93
62. Amit M, Chebath J, Margulets V, Laevsky I, Miropolsky Y, et al. 2010. Suspension culture of undifferentiated human embryonic and induced pluripotent stem cells. Stem Cell Rev. 6(2):248-59
63. Larijani M, Seifinejad A, Pournasr B, Hajihoseini V, Hassani SN, et al. 2011. Long-term maintenance of undifferentiated human embryonic and induced pluripotent stem cells in suspension. Stem Cells Dev. 20(11):1911-23
64. Kim N, Kim H, Jung I, Kim Y, Kim D, Han YM. 2011. Expression profiles of miRNAs in human embryonic stem cells during hepatocyte differentiation. Hepatol. Res. 41(2):170-83
65. Guttman M, Donaghey J, Carey B, Garber M, Grenier J, et al. 2011. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 477:295-300
66. Hay DC. 2010. Cadaveric hepatocytes repopulate diseased livers: life after death. Gastroenterology 139(3):729-31
67. Yusa K, Rashid S, Strick-Marhand H, Varela I, Liu PQ, et al. 2011. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478:391-94
68. Payne C, Samuel K, Pryde A, King J, Brownstein D, et al. 2010. Persistence of functional hepatocyte-like cells in immune-compromised mice. Liver Int. 31:254-62
69. Melkoumian Z, Weber J,Weber D, Fadeev A, Zhou Y, et al. 2010. Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. Nat. Biotechnol. 28:606-10
70. Villa-Diaz LG, Nandivada H, Ding J, Nogueira-De-Souza NC, Krebsbach PH, et al. 2010. Synthetic polymer coatings for long-term growth of human embryonic stem cells. Nat. Biotechnol. 28(6):581-83
71. Rodin S, Domogatskaya A, Str ̈om S, Hansson EM, Chien KR, et al. 2010. Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. Nat. Biotechnol. 28(6):611-15
72. Kraehenbuehl T, Langer R, Ferreira L. 2011. Three-dimensional biomaterials for the study of human pluripotent stem cells. Nat. Methods 8(9):731-36
73. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. 2008. Generation of mouse-induced pluripotent stem cells without viral vectors. Science 322(5903):949-53
74. Nishimura K, Sano M, Ohtaka M, Furuta B, et al. 2010. Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J. Biol. Chem. 286(6):4760-71
75. Warren L,Manos P, Ahfeldt T, Loh T, Li H, et al. 2010. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:618-30
76. Lin S-H, Chang DC, Lin C-H, Ying S-Y, Leu D,Wu DT. 2011. Regulation of somatic cell reprogramming through inducible mir-302 expression. Nucleic Acids Res. 39:1054-65
77. Anokye-Danson F, Trivedi CM, Juhr D, Gupta M, Cui Z, et al. 2011. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 8:376-88
78. Hong H, Takahashi K, Ichisaka T, Takashi A, Ichisaka T, et al. 2009. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460:1132-35
79. Fusaki N, BanH,Nishiyama A, Saeki K,Hasegawa M. 2009. Efficient induction of transgene-free human pluripotent stem cells using vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 85(8):348-62
80. Kim K, Doi A, Wen B, NG K, Zhao R, et al. 2010. Epigenetic memory in induced pluripotent stem cells. Nature 467:285-90
81. Stadtfeld M, Apostolou E, Akutsu H, Fukuda A, Follett P, et al. 2010. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 465:175-81
82. Zhu H, Lensch M, Cahan P, Daley G. 2011. Investigating monogenic and complex diseases with pluripotent stem cells. Nat. Rev. 12:266-71